{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:14Z","timestamp":1740134894702,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,24]]},"DOI":"10.1182\/blood.2019002806","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:35:30Z","timestamp":1571931330000},"page":"1364-1365","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["TFH lymphomas: the times they aza-changin\u2019?"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"17","key":"2019111523110526400_B1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase I study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2019111523110526400_B2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111523110526400_B3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"10168","key":"2019111523110526400_B4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2019;393(10168):228]","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"2019111523110526400_B5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111523110526400_B6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-017-0047-2","article-title":"Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways","volume":"8","author":"Willemsen","year":"2018","journal-title":"Blood Cancer J"},{"issue":"4","key":"2019111523110526400_B7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111523110526400_B8","article-title":"In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory T-cell lymphoma [abstract]","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111523110526400_B9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"2","key":"2019111523110526400_B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1364\/1502387\/bloodbld2019002806c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1364\/1502387\/bloodbld2019002806c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:20:43Z","timestamp":1573863643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/17\/1364\/387161\/TFH-lymphomas-the-times-they-azachangin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":10,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002806","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}